Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

6.12HKD
18 Feb 2019
Change (% chg)

HK$0.18 (+3.03%)
Prev Close
HK$5.94
Open
HK$5.99
Day's High
HK$6.18
Day's Low
HK$5.99
Volume
6,644,675
Avg. Vol
9,524,067
52-wk High
HK$9.86
52-wk Low
HK$4.88

Latest Key Developments (Source: Significant Developments)

Luye Pharma Reaches Strategic Partnership With Astrazeneca, Strengthens Commitment To Cardiovascular Therapeutic Field
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA REACHES STRATEGIC PARTNERSHIP WITH ASTRAZENECA, STRENGTHENS COMMITMENT TO CARDIOVASCULAR THERAPEUTIC FIELD.LUYE PHARMA GROUP LTD - GRANTS ASTRAZENECA EXCLUSIVES RIGHTS TO PROMOTE XUEZHIKANG CAPSULES IN MAINLAND CHINA.LUYE PHARMA - AGREEMENT WITH ASTRAZENECA CHINA GRANT ASTRAZENECA CHINA EXCLUSIVE RIGHTS TO PROMOTE CO'S XUEZHIKANG CAPSULES IN MAINLAND CHINA.LUYE PHARMA - CO, ASTRAZENECA CHINA ARE DISCUSSING POSSIBILITY OF EXPANDING XUEZHIKANG TO U.S. AND EUROPE.  Full Article

Luye Pharma Announces Clinical Trial Application Of Biological Antibody LY09004 Accepted By NMPA In China
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ACCORDING TO SHANDONG BOAN BIOLOGICAL TECHNOLOGY CO, CLINICAL TRIAL APPLICATION OF BIOLOGICAL ANTIBODY LY09004 ACCEPTED BY NMPA IN CHINA.  Full Article

Luye Pharma Announces Approval From U.S. FDA For Clinical Trial For LY03010
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ANNOUNCES APPROVAL FROM U.S. FDA FOR CLINICAL TRIAL FOR LY03010.PALIPERIDONE PALMITATE INJECTABLE SUSPENSION OBTAINED APPROVAL FROM U.S FOOD AND DRUG ADMINISTRATION TO INITIATE CLINICAL TRIALS.  Full Article

Luye Pharma Group Says Registration Application Of Rivastigmine Transdermal Patch Accepted
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Luye Pharma Group Ltd <2186.HK>::REGISTRATION APPLICATION OF RIVASTIGMINE TRANSDERMAL PATCH ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

Luye Pharma Group Gets Approval For New Chemical Drug LY03012 To Initiate Clinical Trials
Monday, 3 Sep 2018 

Sept 3 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP - NEW CHEMICAL DRUG LY03012 APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION IN CHINA TO INITIATE CLINICAL TRIALS.  Full Article

Luye Pharma Group Ltd H1 Net Profit Up 45.2%
Sunday, 26 Aug 2018 

Aug 27 (Reuters) - Luye Pharma Group Ltd <2186.HK>::H1 NET PROFIT INCREASED BY 45.2 PCT TO RMB563.2 MILLION.H1 REVENUE UP 19.1 PCT TO RMB2,203.8 MILLION.BOARD DECLARED AN INTERIM DIVIDEND OF RMB0.043 PER SHARE.  Full Article

Luye Pharma Group's Unit Luye Pharma Switzerland To Borrow EUR120 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT LUYE PHARMA SWITZERLAND TO BORROW EUR120 MILLION.LOAN UNDER FACILITY AGREEMENT WILL BE APPLIED TO REPAY UNIT'S SHAREHOLDER'S LOAN TO LOWER FINANCE COST OF GROUP.  Full Article

Luye Pharma Group Announces Approval For Clinical Trial Of Anti-Tumor Innovative Drug (LY01013) In China
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ANNOUNCES APPROVAL FOR CLINICAL TRIAL FOR CLASS I NEW CHEMICAL DRUG, ANTI-TUMOR INNOVATIVE DRUG (LY01013) IN CHINA.  Full Article

Luye Pharma Says Unit Luye Hong Kong To Borrow Term Loan Of Up To $300 Mln
Friday, 22 Jun 2018 

June 22 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT LUYE HONG KONG TO BORROW A TERM LOAN FACILITY OF UP TO US$300 MILLION.  Full Article

Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​
Monday, 26 Mar 2018 

March 26 (Reuters) - Luye Pharma Group Ltd <2186.HK>::BOARD DECLARED A FINAL DIVIDEND OF RMB0.045 PER SHARE.FY REVENUE UP 30.7% TO RMB3,814.8 MILLION.‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​.  Full Article